Medications

US regulators to decide on new weight loss drug

US regulators were expected to decide Tuesday whether to approve the second new anti-obesity drug in 13 years, Qnexa, which studies have shown may help some people lose up to 10 percent of their body weight.

Medical research

Bone-derived hormone suppresses appetite in mice

A hormone secreted by bone cells can suppress appetite, according to mouse studies conducted by Columbia University Medical Center (CUMC) researchers. The hormone—called lipocalin 2—turns on neurons in the brain that ...

Medications

England eyes expanding access to weight-loss drugs

Doctors in England's state-run health service could soon be allowed to prescribe more people with obesity weight-loss drugs under a new pilot scheme, the government said Wednesday.

Medications

Cometriq approved for rare thyroid cancer

(HealthDay)—Cometriq (cabozantinib) has been approved by the U.S. Food and Drug Administration to treat modullary thyroid cancer that has spread to other parts of the body, the agency said Thursday.

Medications

FDA to decide on Qnexa obesity drug in July

US regulators will decide in July whether to approve Qnexa, the first obesity drug in more than a decade, extending the initial deadline by three months, the California-based drug-maker VIVUS said.

Surgery

Factors affecting weight loss after abdominoplasty identified

(HealthDay)—For patients undergoing abdominoplasty, weight loss is associated with having a preoperative body mass index ≥24.5 kg/m² and is attributed to increased satiety in most patients, according to a study published ...

Medications

French drugmaker, watchdog on trial over weight loss pill deaths

France's medicines watchdog and pharma firm Servier went on trial on fraud and negligence charges on Monday over the use of a diabetes pill prescribed for weight loss that has been blamed for the deaths of hundreds of people.

page 2 from 3